Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allopurinol and Trimetazidine for CA-AKI Prevention in PCI
NCT05540184Phase 4Unknown
- Sponsor
- Beni Suef University
- Start
- Sep 2022
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of trimetazidine, allopurinol in contrast-associated acute kidney injury (CA-AKI), sponsored by Beni Suef University. Status: unknown.
02
Drugs
trimetazidineallopurinol
03
Conditions
contrast-associated acute kidney injury (CA-AKI)
Beyond the preview
Go deeper on NCT05540184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05540184.